Associated Genetic Biomarkers
Exportin 1 (XPO1) is a gene that encodes a protein that medicates leucine-rich nuclear export signal-dependent protein transport and inhibits nuclear export of specific molecules. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
XPO1 is altered in 0.95% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in XPO1 are XPO1 Mutation (0.97%), XPO1 Amplification (0.12%), XPO1 E571K (0.09%), XPO1 R749Q (0.04%), and XPO1 R261Q (0.01%) .
XPO1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status as an inclusion criterion, 1 is phase 1 (0 open).
Trials with XPO1 status in the inclusion eligibility criteria most commonly target bladder carcinoma, breast carcinoma, colorectal carcinoma, head and neck carcinoma, and lymphoma .
The most frequent alteration to serve as an inclusion eligibility criterion is XPO1 Mutation .
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials with XPO1 as an inclusion criteria .
Significance of XPO1 in Diseases
Anaplastic Astrocytoma +
Bladder Carcinoma +
Colorectal Carcinoma +
Malignant Solid Tumor +
Breast Carcinoma +
Non-Small Cell Lung Carcinoma +
XPO1 is altered in 0.86% of non-small cell lung carcinoma patients .
XPO1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Pancreatic Carcinoma +
Ovarian Carcinoma +
Head And Neck Carcinoma +
XPO1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.